Do analysts prefer CELU or VTGN?

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 295.83%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Do analysts recommend VTGN or IZTC?

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, VTGN or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VistaGen Therapeutics $1.27M 8.39 -$69.68M -$1.66 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Do analysts recommend VTGN or ATYR?

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics' higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

VistaGen Therapeutics (VTGN) Competitors

$0.24 +0.01 (+2.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.24 +0.01 (+2.08%)

As of 09/18/2026 07:59 PM Eastern

Compare

VTGN vs. ATNM, CELU, EDSA, IZTC, and ATYR

Should you buy VistaGen Therapeutics stock or one of its competitors? VistaGen Therapeutics's main competitors and comparable companies include Actinium Pharmaceuticals (ATNM), Celularity (CELU), Edesa Biotech (EDSA), Invizyne Technologies (IZTC), and aTyr Pharma (ATYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Actinium Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Actinium Pharmaceuticals' return on equity of -100.85% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Actinium Pharmaceuticals has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

In the previous week, Actinium Pharmaceuticals had 7 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 0 mentions for VistaGen Therapeutics. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat VistaGen Therapeutics' score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Positive
VistaGen Therapeutics	Neutral

Actinium Pharmaceuticals has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39
VistaGen Therapeutics	$1.27M	8.39	-$69.68M	-$1.66	N/A

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 309.84%. VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 295.83%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Actinium Pharmaceuticals is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Actinium Pharmaceuticals beats VistaGen Therapeutics on 11 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Celularity?

Celularity (NASDAQ:CELU) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

In the previous week, Celularity had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 1 mentions for Celularity and 0 mentions for VistaGen Therapeutics. Celularity's average media sentiment score of 0.00 equaled VistaGen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
VistaGen Therapeutics	Neutral

19.0% of Celularity shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Celularity has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

VistaGen Therapeutics has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.43	-$91.72M	-$3.33	N/A
VistaGen Therapeutics	$1.27M	8.39	-$69.68M	-$1.66	N/A

Celularity has a net margin of -345.45% compared to VistaGen Therapeutics' net margin of -2,702.64%. Celularity's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 295.83%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Celularity and VistaGen Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Edesa Biotech currently has a consensus target price of $5.00, indicating a potential upside of 20.77%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics' higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Edesa Biotech has higher earnings, but lower revenue than VistaGen Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
VistaGen Therapeutics	$1.27M	8.39	-$69.68M	-$1.66	N/A

Edesa Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

In the previous week, Edesa Biotech had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for VistaGen Therapeutics. Edesa Biotech's average media sentiment score of 0.63 beat VistaGen Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Positive
VistaGen Therapeutics	Neutral

Edesa Biotech has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Edesa Biotech beats VistaGen Therapeutics on 10 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Invizyne Technologies?

VistaGen Therapeutics (NASDAQ:VTGN) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

78.4% of VistaGen Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Invizyne Technologies has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Invizyne Technologies' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Invizyne Technologies	N/A	N/A	N/A

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, VistaGen Therapeutics' average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Invizyne Technologies	Neutral

Invizyne Technologies has lower revenue, but higher earnings than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.39	-$69.68M	-$1.66	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

VistaGen Therapeutics beats Invizyne Technologies on 5 of the 8 factors compared between the two stocks.

How does VistaGen Therapeutics compare to aTyr Pharma?

VistaGen Therapeutics (NASDAQ:VTGN) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

aTyr Pharma has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. aTyr Pharma's return on equity of -95.89% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
aTyr Pharma	N/A	-95.89%	-69.67%

In the previous week, aTyr Pharma had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 1 mentions for aTyr Pharma and 0 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
aTyr Pharma	Neutral

VistaGen Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics' higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

VistaGen Therapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.39	-$69.68M	-$1.66	N/A
aTyr Pharma	$190K	187.40	-$74.12M	-$0.62	N/A

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats VistaGen Therapeutics on 11 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.65M	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-0.14	14.23	275.49	25.40
Price / Sales	8.39	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.27	15.45	10.46	6.33
Net Income	-$69.68M	-$22.86M	$3.49B	$358.33M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	-0.46%	-3.29%	-1.74%	-2.39%
1 Year Performance	-91.95%	37.74%	18.13%	5.35%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	1.7236 of 5 stars	$0.24 +2.7%	$0.95 +295.8%	-91.9%	$10.65M	$1.27M	N/A	41
ATNM Actinium Pharmaceuticals	2.6764 of 5 stars	$1.29 +0.8%	$5.00 +287.6%	-23.3%	$40.53M	$35.09M	N/A	30	News Coverage Analyst Revision
CELU Celularity	0.1924 of 5 stars	$1.38 -1.6%	N/A	-41.0%	$40.09M	$26.55M	N/A	220
EDSA Edesa Biotech	1.9035 of 5 stars	$4.14 flat	$5.00 +20.8%	+67.6%	$39.92M	N/A	N/A	20	Analyst Upgrade
IZTC Invizyne Technologies	N/A	$6.30 +2.1%	N/A	-52.8%	$39.40M	N/A	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. ATNM, CELU, EDSA, IZTC, and ATYR

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does VistaGen Therapeutics compare to Celularity?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Summary

How does VistaGen Therapeutics compare to Invizyne Technologies?

Summary

How does VistaGen Therapeutics compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. ATNM, CELU, EDSA, IZTC, and ATYR

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Do insiders & institutionals believe in ATNM or VTGN?

Is ATNM or VTGN more profitable?

Which has more volatility and risk, ATNM or VTGN?

Does the media prefer ATNM or VTGN?

Which has better earnings and valuation, ATNM or VTGN?

Do analysts recommend ATNM or VTGN?

Summary

How does VistaGen Therapeutics compare to Celularity?

Does the media refer more to CELU or VTGN?

Do institutionals & insiders believe in CELU or VTGN?

Which has more volatility & risk, CELU or VTGN?

Which has stronger earnings and valuation, CELU or VTGN?

Is CELU or VTGN more profitable?

Do analysts prefer CELU or VTGN?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Do institutionals and insiders have more ownership in EDSA or VTGN?

Do analysts rate EDSA or VTGN?

Which has stronger valuation and earnings, EDSA or VTGN?

Is EDSA or VTGN more profitable?

Does the media refer more to EDSA or VTGN?

Which has more volatility & risk, EDSA or VTGN?

Summary

How does VistaGen Therapeutics compare to Invizyne Technologies?

Do institutionals & insiders believe in VTGN or IZTC?

Is VTGN or IZTC more profitable?

Do analysts recommend VTGN or IZTC?

Does the media favor VTGN or IZTC?

Which has stronger earnings & valuation, VTGN or IZTC?

Summary

How does VistaGen Therapeutics compare to aTyr Pharma?

Is VTGN or ATYR more profitable?

Does the media favor VTGN or ATYR?

Which has more risk & volatility, VTGN or ATYR?

Do analysts recommend VTGN or ATYR?

Which has better valuation & earnings, VTGN or ATYR?

Do institutionals and insiders believe in VTGN or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools